Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Rationale and design of the phase 3a development programme (ONWARDS 1–6 trials) investigating once‐weekly insulin icodec in diabetes
Athena Philis‐Tsimikas, Harpreet S. Bajaj, Kamilla Begtrup, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 2, pp. 331-341
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin
Julio Rosenstock, Stephen C. Bain, Amoolya Gowda, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 4, pp. 297-308
Open Access | Times Cited: 92
Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial
Chantal Mathieu, Björg Ásbjörnsdóttir, Harpreet S. Bajaj, et al.
The Lancet (2023) Vol. 401, Iss. 10392, pp. 1929-1940
Closed Access | Times Cited: 86
Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial
Athena Philis‐Tsimikas, Marisse Asong, Edward Franek, et al.
The Lancet Diabetes & Endocrinology (2023) Vol. 11, Iss. 6, pp. 414-425
Closed Access | Times Cited: 85
Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes
Ildiko Lingvay, Marisse Asong, Cyrus Desouza, et al.
JAMA (2023) Vol. 330, Iss. 3, pp. 228-228
Open Access | Times Cited: 82
Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial
David Russell‐Jones, Tetsuya Babazono, Roman Cailleteau, et al.
The Lancet (2023) Vol. 402, Iss. 10413, pp. 1636-1647
Open Access | Times Cited: 53
Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5)
Harpreet S. Bajaj, Jens Aberle, Melanie J. Davies, et al.
Annals of Internal Medicine (2023) Vol. 176, Iss. 11, pp. 1476-1485
Closed Access | Times Cited: 50
The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa
Julio Rosenstock, Rattan Juneja, John M. Beals, et al.
Endocrine Reviews (2024) Vol. 45, Iss. 3, pp. 379-413
Open Access | Times Cited: 30
Continuous Glucose Monitoring–Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodec: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4
Harpreet S. Bajaj, Björg Ásbjörnsdóttir, Lisbeth Carstensen, et al.
Diabetes Care (2024) Vol. 47, Iss. 4, pp. 729-738
Open Access | Times Cited: 10
Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes
Roberto Trevisan, Matteo Conti, Stefano Ciardullo
Diabetologia (2024) Vol. 67, Iss. 8, pp. 1480-1492
Open Access | Times Cited: 10
Pharmacokinetic and pharmacodynamic properties of once‐weekly insulin icodec in individuals with type 2 diabetes
Thomas R. Pieber, Marisse Asong, Gabriele Fluhr, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 12, pp. 3716-3723
Open Access | Times Cited: 18
Once‐weekly insulin icodec compared with daily basal insulin analogues in type 2 diabetes: Participant‐level meta‐analysis of the ONWARDS 1–5 trials
Harpreet S. Bajaj, Björg Ásbjörnsdóttir, Tanvir Johanning Bari, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 9, pp. 3810-3820
Open Access | Times Cited: 7
Evaluating Patient and Provider Preferences for a Once-Weekly Basal Insulin in Adults with Type 2 Diabetes
David Kerr, Jigar Rajpura, Tarlan Namvar
Patient Preference and Adherence (2024) Vol. Volume 18, pp. 411-424
Open Access | Times Cited: 6
Insulin Icodec Weekly: A Basal Insulin Analogue for Type 2 Diabetes
Harpreet S. Bajaj, Ronald Goldenberg
touchREVIEWS in Endocrinology (2023) Vol. 19, Iss. 1, pp. 4-4
Open Access | Times Cited: 13
Current usage of long-acting insulin analogs in patients with type 2 diabetes mellitus
Gülali Aktaş, Tuba Taslamacıoğlu Duman
Expert Review of Endocrinology & Metabolism (2024) Vol. 19, Iss. 2, pp. 155-161
Closed Access | Times Cited: 5
The rise of weekly insulins: addressing the challenges of type 2 diabetes care in Brazil
André Gustavo Daher Vianna, Diana Alves, Taís Silveira Assmann, et al.
Diabetology & Metabolic Syndrome (2025) Vol. 17, Iss. 1
Open Access
Once-Weekly Insulins
J. Hans DeVries, Tim Heise
Diabetes Technology & Therapeutics (2025)
Closed Access
Efficacy and hypoglycaemia outcomes with once‐weekly insulin icodec versus once‐daily basal insulin in individuals with type 2 diabetes by kidney function: A post hoc participant‐level analysis of the ONWARDS 1–5 trials
Peter Rossing, Malik Benamar, Alice Cheng, et al.
Diabetes Obesity and Metabolism (2025)
Open Access
Once-Weekly Insulin Icodec Versus Once-Daily Insulin Degludec in Insulin-Naive Chinese Participants with Type 2 Diabetes: A Post Hoc Analysis of ONWARDS 3
Yijun Li, Soumitra Kar, Congcong Li, et al.
Diabetes Therapy (2025)
Open Access
Efficacy and hypoglycaemia outcomes with once‐weekly insulin icodec versus once‐daily basal insulin in type 2 diabetes according to baseline glucagon‐like peptide‐1 receptor agonist and sodium‐glucose co‐transporter‐2 inhibitor use: A post hoc analysis of ONWARDS 1–5
Tina Vilsbøll, Ariel Fu, Monika Kellerer, et al.
Diabetes Obesity and Metabolism (2025)
Open Access
Insulin icodec: A novel once-weekly formulation for the treatment of type 1 and type 2 diabetes mellitus
David Q. Pham, John Andraos, Joelle Ayoub
Reviews in Endocrine and Metabolic Disorders (2025)
Open Access
The effect of once-weekly insulin icodec vs once-daily basal insulin on physical activity-attributed hypoglycaemia in type 2 diabetes: a post hoc analysis of ONWARDS 1–5
Michael C. Riddell, Simon Heller, Lisbeth Carstensen, et al.
Diabetologia (2025)
Open Access
Bridging the Gap: A Literature Review of Advancements in Obesity and Diabetes Mellitus Management
Gheorghe Nicușor Pop, Felicia Manole, Florina Buleu, et al.
Applied Sciences (2024) Vol. 14, Iss. 15, pp. 6565-6565
Open Access | Times Cited: 3
Improved treatment satisfaction with once-weekly insulin icodec compared with once-daily basal insulin in individuals with type 2 diabetes: An analysis of patient-reported outcomes and participant interviews from ONWARDS 2 and 5 and a physician survey from ONWARDS 1
William H. Polonsky, Malik Benamar, Lisbeth Carstensen, et al.
Diabetes Research and Clinical Practice (2024), pp. 111885-111885
Open Access | Times Cited: 3
Pharmacokinetic Properties of a Once-Weekly Fixed-Ratio Combination of Insulin Icodec and Semaglutide Compared with Separate Administration of Each Component in Individuals with Type 2 Diabetes Mellitus
Lisbet Westergaard, Lene Alifrangis, Stephen T. Buckley, et al.
Clinical Drug Investigation (2024) Vol. 44, Iss. 11, pp. 849-861
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top